PD-325901

SKU: orb1300996

Featured

Description

Mirdametinib (PD325901) is a potent, selective, and orally active non-ATP-competitive MEK inhibitor (IC50=0.33 nM). It demonstrates antitumor activity in research models by suppressing p-ERK1/2 and promoting apoptosis, making it a valuable tool for studying MAPK/ERK pathway dysregulation in cancer, both in vitro and in vivo.

Research Area

Stem Cell & Developmental Biology

Images & Validation

−

Key Properties

−

CAS Number	391210-10-9
MW	482.20
Purity	> 98%
Formula	C₁₆H₁₄F₃IN₂O₄
SMILES	OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F
Target	Kinase
Solubility	Soluble in DMSO (up to 12 mg/ml)

Bioactivity

−

Target IC50	MEK1:1 nM (Ki)\|MEK2:1 nM (Ki)\|MEK:0.33 nM (cell free)
In Vivo	METHODS: To assay antitumor activity in vivo, Mirdametinib (20-25 mg/kg, 80 mmol/L citric buffer (pH 7)) was administered by gavage to Athymic Ncr-nu/nu mice harboring PTC tumors K2 or TPC-1 five times per week for three weeks. RESULTS: Mirdametinib completely inhibited tumor growth in mice inoculated with PTC cells K2 harboring BRAF mutations and significantly reduced tumor growth in mice inoculated with PTC cells TPC-1 harboring RET/PTC1 rearrangements. METHODS: To assay anti-tumor activity in vivo, Mirdametinib (1.6-25 mg/kg, 0.5% hydroxypropylmethylcellulose + 0.2% Tween 80 in water) was administered orally to mice bearing mouse colorectal cancer tumor CT26 once daily for fourteen days. RESULTS: Mirdametinib significantly inhibited pERK levels in tumors. Read more...
In Vitro	METHODS: Eleven human melanoma cell lines were treated with Mirdametinib (0.1-1000 nM) for 72 h, and cell counts were determined using the trypan blue exclusion test. RESULTS: Mirdametinib (IC50=20-50 nM) effectively inhibited the growth of human melanoma cell lines with BRAF mutations (M14/A375P/A375M/A375SM/ME10538/ME4686/JR8) or without BRAF mutations (ME4405/ME13923). ME8959 both have wild-type BRAF and are slightly more resistant to Mirdametinib-mediated growth inhibition (IC50≥100 nM). METHODS: Papillary thyroid carcinoma (PTC) cell lines K2 and TPC-1 were treated with Mirdametinib (0.1-1000 nmol/L) for 1-96 h. Target protein expression levels were detected by Western Blot. RESULTS: Mirdametinib effectively inhibited the phosphorylation of ERK1/2 in various PTC cell lines. Read more...
Cell Research	A cell death detection enzyme-linked immunosorbent assay was used per the manufacturer's instructions. Briefly, 4 × 10^4 cells were plated in 24-well plates in triplicate the day before treatment. PTC cells were treated with 0.1 μmol/L PD0325901 for 96 hours. Cells treated with 1 μmol/L staurosporine served as positive controls for apoptosis. At the end of treatment, cells were lysed using the lysis buffer provided in the kit for 30 minutes at room temperature and then centrifuged in 24-well plates. Lysates (20 μL of supernatant) were transferred to streptavidin-coated wells and incubated for 2 hours at room temperature with two antibodies (biotin-labeled anti-histone antibody and peroxidase-conjugated anti-DNA antibody). After the wells were washed three times, the samples were incubated with peroxidase substrate (ABTS) and the amount of colored product was determined spectrophotometrically at 405 nm. The background was measured at 490 nm . Read more...
Animal Research	Athymic Ncr-nu/nu mice were obtained from the National Cancer Institute at ages 6 to 8 weeks and housed for at least 1 week after arrival. Mice (10–14 per group) were anesthetized s.c. with a cocktail (100 μL/10 g body weight of 10 mg/mL ketamine and 1 mg/mL xylazine). K2 and TPC-1 cells stably infected with a retrovirus expressing luciferase (5 × 105 cells in 5 μL RPMI1640 medium) were inoculated into the thyroid gland, and the mice were monitored weekly for tumor growth by Xenogen (IVIS 200 imaging system) using Living Image 3.0 software. One week after inoculation, PD0325901 was dissolved in 80 mmol/L citric buffer (pH 7) by sonication and given to mice daily by oral gavage (20–25 mg/kg) for 3 weeks (5 consecutive days/week). Mice were sacrificed only due to tumor burden or loss of 20% of body weight. Tumor sizes were measured with calipers and tumor volume (V) was calculated by the formula (V = length × width × depth). Control mice were given 80 mmol/L citric buffer (pH 7) alone. All in vivo experiments were done at least twice . Read more...

Storage & Handling

−

Storage	RT
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

Autophagy, Apoptosis, inhibit, Mitogen-activated protein kinase kinase, Mirdametinib, PD325901, PD-325901, PD0325901, PD-0325901, PD 0325901, PD 325901, Inhibitor, MAP2K, MAPKK, MEK

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID

9826528 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols

PD-325901 (orb1300996)

Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

No reviews yet

PD-325901

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Similar Products

PD-325901 [orb3066680]

Quality Guarantee

Compound Identifiers

Key Properties

Documents Download

Request a Document

Protocol Information

PD-325901 (orb1300996)

Step 1: Enter information below

Step 2: Enter the in vivo formulation

Available Sizes

Email

UK Office

US Office

CN Office

Distributors